SCHEMBL16795704

SCHEMBL16795704

C=C(CO)c1ccc(OC)c(OC)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 2/20 0.55
CYP2C19 P33261 2/20 0.55
TSHR P16473 2/20 0.55
CYP1A2 P05177 1/20 0.55
CYP3A4 P08684 1/20 0.55
PDE4A P27815 5/20 0.54
PDE4B Q07343 5/20 0.54
PDE4C Q08493 5/20 0.54
PDE4D Q08499 5/20 0.54
CA12 O43570 1/20 0.53
CA1 P00915 1/20 0.53
CA2 P00918 1/20 0.53
CA4 P22748 1/20 0.53
CA6 P23280 1/20 0.53
CA7 P43166 1/20 0.53
TPMT P51580 1/20 0.53
CA9 Q16790 1/20 0.53
CA14 Q9ULX7 1/20 0.53
GAA P10253 2/20 0.50
MEN1 O00255 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16795739 0.85 ALOX15 (0.49) CYP2C9CYP2C19TSHRCYP1A2CYP3A4
SCHEMBL8297344 0.85 MEN1 (0.59) CYP2C9CYP2C19TSHRCYP1A2CYP3A4
SCHEMBL16795854 0.84 LMNA (0.41) CYP2C9CYP2C19TSHRCYP1A2CYP3A4
SCHEMBL16795557 0.84 HTT (0.57) PDE4APDE4BPDE4CPDE4DMEN1
SCHEMBL14611953 0.83 MAOB (0.58) CYP2C9CYP2C19TSHRCYP1A2CYP3A4
SCHEMBL8152340 0.83 CYP2C9 (0.53) CYP2C9CYP2C19TSHRCYP1A2CYP3A4
SCHEMBL16795747 0.82 NPC1 (0.64) MEN1KMT2AHPGDPRSS1
SCHEMBL10131587 0.81 TSHR (0.52) CYP2C9CYP2C19TSHRCYP1A2CYP3A4
SCHEMBL14375953 0.79 PDE4A (0.79) CYP2C9CYP2C19TSHRCYP1A2CYP3A4
SCHEMBL24147822 0.79 TSHR (0.58) CYP2C9CYP2C19TSHRCYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2015087094-A1 NEW ARYLALKENYLPROPARGYLAMINE DERIVATIVES EXHIBITING NEUROPROTECTIVE ACTION FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SEMMELWEIS EGYETEM (HU) 2015-06-18 WO disclosed